




Background: Methamphetamine use disorder is a persistent and prevalent illness associated with 
serious physical, emotional, cognitive and social harms. No proven pharmacological treatments 
have yet been identified and psychological therapies are currently the only evidence based 
treatments. A recent systematic review and meta-analysis found no quantitative evidence of 
benefit for psychostimulants in achieving abstinence or retention in treatment, but that review 
was limited to specific pharmacological agents (Bhatt et al, 2016). An older systematic review 
examined all treatments and found no single agent that demonstrated consistent efficacy 
(Brackins et al, 2011). Many additional studies have since been published. The aim of this 
systematic review is to critically evaluate the literature not previously covered by these and 
examine the evidence for efficacy of all possible pharmacological treatments. 
Methods: The literature search strategy consisted of an electronic search of PubMed. I included 
randomized controlled trials not previously reviewed of any pharmacological treatment for 
methamphetamine use disorder that reported methamphetamine use by urine drug screen as an 
outcome. I abstracted data from all identified studies using a standardized data collection 
instrument and critically analyzed the risk of bias, internal validity and external validity of all 
studies using a standardized form. I synthesized the review data.  
Results: I identified and analyzed 11 studies not previously reviewed. Pharmacological 
treatments used in these studies included buprenorphine, N-acetyl-cysteine, aripiprazole, 
citocoline, topiramate, naltrexone, mirtazapine, and a combined regimen of 
flumazenil/gabapentin/hydroxyzine. No study was found to have both good internal and good 
external validity. The overall level of internal validity within studies was severely limited by 
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small study size and high numbers of drop outs. Comparison between studies was often not 
possible due to inconsistently measured, defined and reported outcome measures.  
Conclusions: Several studies reported positive results, but were limited by poor internal or 
external validity and no evidence was found to support treatment of methamphetamine use 
disorder with a specific medication in the general outpatient population. There is a pressing need 
for more research in this field. Future trials should use consistent outcome measures and address 
possible challenges to statistical power caused by high attrition. 
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Methamphetamine use is a persistent and prevalent illness worldwide associated with serious 
physical, emotional, cognitive and social harms. Taken together, methamphetamine and 
amphetamine type stimulants have become the most popular psychostimulants in the world, with 
24 million users worldwide.1Although the use of amphetamines other than methamphetamine is 
on the rise, methamphetamine still accounted for 71% of all seizures of amphetamine type 
stimulants in 2011.1 In the US in 2014, 1.6 million people used a stimulant drug for non-medical 
purposes, 569,000 of whom were current methamphetamine users, representing 0.2% of the total 
population. These numbers were similar to those from 2002-2013.2 
Amphetamine was first synthesized from the Chinese herb Ma Huang in the early 19th century.1 
Illegal methamphetamine recreational use first appeared in the United States in the 1930’s. 3 
Methamphetamine and other related amphetamines were actually prescribed by physicians in the 
US up until the 1960’s for weight loss and depression.4 An illegal powder form known variously 
as “crank” or “meth” or “crystal” became available in the 1980’s when there was surge in 
methamphetamine use in the US. Then, in 1988, a form of methamphetamine that could be 
smoked known as “ice” or “glass” was identified first in Hawaii and then spread to the rest of the 
US.5 
Methamphetamine use is associated with many medical problems such as infectious disease 
including HIV, cardiovascular and pulmonary disease, anxiety, depression, psychosis and 
impaired cognition. It is also associated with an increased risk of mortality, primarily from HIV, 
cardiovascular disease, or overdose.6 Amphetamine dependence has been calculated to account 




The mainstay of treatment for methamphetamine abuse remains psychological treatments, which 
have been supported by numerous trials and systematic reviews.8 All psychosocial treatments 
have shown efficacy, with contingency management having the strongest evidence.9  
An effective pharmacological treatment for methamphetamine abuse to complement physical 
treatments could potentially play a major role in reducing the harms associated with the abuse. 
The possibility of an effective pharmacological treatment has been suggested by advances in the 
understanding of the neurochemical pathways associated with its use, as well as the experience 
of effective pharmacological treatments for opioid and alcohol abuse.  
While pharmacological treatment options are widely available for both opioid and alcohol abuse, 
the general consensus among primary care physicians and those who specialize in addiction 
treatment is that no pharmacological treatments have been shown to be effective treatments of 
methamphetamine abuse in research of good quality. 
Three basic approaches for a pharmacological treatment of methamphetamine use can be 
postulated: (1) Agonist therapy, in which a medication replaces the effects of methamphetamine 
as methadone does for opioid dependence; (2) Antagonist therapy, in which the medication 
blocks the effects of methamphetamine in the same way naltrexone does for opioid dependence; 
and (3) Symptomatic treatments that attempt to ameliorate the negative effects of use or 
withdrawal.10 
To my knowledge, 4 systematic reviews of treatments for methamphetamine abuse have been 
published in addition to several non-systematic narrative reviews. The most recent and well-
conducted was a Cochrane review and meta-analysis published in November 2016 that updated a 




psychostimulant, or agonist, treatments.11,12 Another systematic review published in 2004 
similarly reviewed only agonist treatments for methamphetamine abuse.10 A systematic review 
published by Shoptaw et all in 2009 examined only treatments for methamphetamine 
withdrawal.13 Only one other systematic review published in 2011 reviewed all possible 
pharmacological treatments for methamphetamine abuse.14  While agonist treatment is a 
promising avenue for treatment of methamphetamine abuse, antagonist treatments and 
symptomatic treatments may also be a useful addition to the pharmacological armamentarium.  
The most recent systematic review and meta-analysis by Bhatt et al found no quantitative 
evidence of benefit for psychostimulants in achieving abstinence or retention in treatment, but 
this review was limited to specific pharmacological agents.11 An older systematic review by 
Brackins et al examined all treatments and found no single agent that demonstrated consistent 
efficacy.15 Many additional studies have been published since that comprehensive review in 
2012, as evidenced by the updated findings in the meta-analysis of psychostimulant treatments.11 
The aim of this systematic review is to critically evaluate the literature not previously covered by 
these and examine the evidence for efficacy of all possible pharmacological treatments.  The key 
question for this review was:  
 
What is the evidence in randomized placebo controlled trials for a pharmacological treatment of 








Where applicable, I have reported the methods and results of this systematic review in 
accordance with the PRISMA guidelines.16  I do not report on elements pertaining to a meta-
analysis. I did not register a study protocol. I formulated the search strategy and analysis 
methods prior to beginning the process of study inclusion/exclusion and data extraction. In the 
original design of the study a secondary objective and analysis method was to review preclinical 
studies in addition to RCT’s and to correlate between the findings of preclinical studies and 
clinical studies in order to guide future selection of candidate therapies. However, after initial 
title and abstract review, due to the number of identified preclinical studies and time constraints, 
I narrowed the scope of the study to clinical RCTs only. 
Data Sources and Searches 
To identify articles for review, I searched PubMed from inception to November 29, 2016. The 
search was limited to studies of human subjects and English language articles. The various 
iterations of the search strategy are outlined in Table 1.  
The final formal algorithm for searching MEDLINE was (("methamphetamine"[MeSH Terms] 
OR "methamphetamine"[All Fields]) OR ("dextroamphetamine"[MeSH Terms] OR 
"dextroamphetamine"[All Fields] OR "amphetamines"[MeSH Terms] OR "amphetamines"[All 
Fields] OR "amphetamine"[All Fields] OR "amphetamine"[MeSH Terms])) AND ("abuse"[All 
Fields] OR "dependence"[All Fields] OR "use"[All Fields] OR "disorder"[All fields] OR 
"Substance-Related Disorders"[MeSH Terms]) AND (("therapy"[Subheading] OR "therapy"[All 
Fields] OR "treatment"[All Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All 
Fields] OR "medication"[All Fields]) OR "amphetamine-related disorders/drug therapy"[MAJR]) 




Eligibility Criteria and Study Selection 
I screened all titles and abstracts identified by the search and selected articles for further 
eligibility review. In order to capture all relevant studies including preclinical studies, I selected 
at screening all articles with titles or abstracts that reported results of a study examining the 
effect of a pharmacological treatment in the setting of methamphetamine use. In cases where 
there was doubt, I selected the article for review. I imported the citations of all selected articles 
into Papers for Mac Version 3.3.1 and downloaded the full PDF of each article. 
In the eligibility review I examined articles in their entirety and excluded articles from the main 
analysis according to the algorithm presented in Figure 1. Exclusion criteria included previously 
reviewed studies (specifically, studies included in the review by Brackins et al or the systematic 
review of agonist treatment by Bhatt et al11,15), studies that included populations without 
methamphetamine use (i.e. studies that included populations with cocaine use but not 
methamphetamine use), studies that included participants younger than 18 years old, studies that 
only examined the effects of behavioral therapies, non-randomized studies, un-controlled studies, 
articles that were reports, commentaries, or re-analyses of other identified articles, or studies that 
did not include reduction in methamphetamine use as an outcome measure. I also excluded pre-
clinical studies that examined cognitive, behavioral, or symptom effects after laboratory based 
administration of medications. Because of the change in DSM criteria during the years of articles 
reviewed, I included studies using any diagnostic criteria for methamphetamine abuse, use or 
dependence. Because methamphetamine use disorder is often a comorbid disorder with other 
drug and psychological conditions, I included studies irrespective of additional diagnoses. I 





Figure 1: Eligibility Criteria 
Data Collection Process and Assessment of Risk of Bias 
I abstracted data from each study using a data extraction chart in Microsoft Excel I adapted from 
the reported methods of Castell et al in their systematic review of treatments for cocaine 
dependence.17 I did not contact authors of articles to obtain missing data or confirm published 
data. Data extracted from each study include: 
• Study description and funding: study author, year, conflicts of interest, funding source 
Duplicate 
Is the study intervention an agonist treatment? 
Has this study been previously reviewed? 
Is this a preclinical study? 
Does this study report only on behavioral treatments? 
Are there participants who don’t use amphetamines? 
Does this study include participants younger than 18? 
Does this study measure amphetamine use? 
Is this a randomized controlled trial? 





















• Methods: sequence generation, allocation concealment, blinding of 
patients/clinicians/therapists/assessors, single or multiple site, study duration, number of 
participants handling of dropouts, instruments used 
• Participants: source population, inclusion criteria, exclusion criteria, sex, age, ethnicity, 
employment status, frequency of methamphetamine use, years of methamphetamine use, 
route, comorbid drug disorders, comorbid psychiatric disorders 
• Intervention and control: drug, dose, control type, adherence, adjunct interventions 
• Outcomes: methamphetamine use by urine drug screen (UDS), retention in treatment, 
methamphetamine craving, self-reported use, number who finished study, reason for drop 
outs, CGI score, psychotic symptoms, anxiety severity, depression severity, cocaine use 
by UDS, opiate use by UDS, number dropped out due to adverse events, number who had 
serious adverse events 
For this review, the primary outcome measure of interest was reduction in methamphetamine use 
as measured by urine drug screens. Secondary outcome measures of interest included retention in 
treatment and methamphetamine craving. 
I assessed the internal and external validity of each included study using a standard chart in 
Microsoft Excel that included 9 items for internal validity, a single summary judgement of 
internal validity and an overall judgement for external validity. I adapted the criteria for items 1-
9 from a recent Cochrane review of treatment for cocaine which was itself based on the 
recommendations in the Cochrane Handbook.17,18 I chose this method of analysis because of its 
standardized form, previous use, and for ease of comparability with the systematic reviews of 




criteria for the assessment of the risk of bias for items 1-9 are presented in Appendix A and are 
taken from the Cochrane Handbook.18 
I added to the assessment of risk of bias a summary item (number 10) on the overall internal 
validity of each study rated as good, fair or poor. This was my own judgement based on the 
likely magnitude and direction of the risks of bias identified in items 1-9. A judgement of poor 
internal validity is meant to indicate that there is a high likelihood that the results have been 
significantly affected by some form of bias to the point of altering the conclusion of the study. A 
judgement of fair internal validity is meant to indicate that two or more significant sources of 
bias were identified but that the likelihood of changing the conclusion of the study was small. A 
judgement of good internal validity is meant to indicate that only one or no significant source of 
bias was identified, and any bias was unlikely to change the conclusion of the study.  
Finally, I included a single judgement of good, fair or poor on the external validity of the results 
as applied to the general outpatient population in the USA who suffer from methamphetamine 
use disorder. A judgement of poor external validity is meant to indicate that the results cannot be 
applied. A judgement of fair external validity is meant to indicate that the results may be 
applicable, but that there were significant differences in the source population compared to the 
general population. A judgment of good external validity was given when the results were felt to 
be directly applicable. 
Data Synthesis and Analysis 
Because of the expected heterogeneity of pharmacological treatments, I did not plan on 
conducting any meta-analyses or computational combination of results identified. Instead, I 




external validity of each study. I also looked for trends in the risks of bias in the identified 
studies to help guide future research.   
Results 
Table 1: Iterations of Search Strategy 
Search Search Term Results 
1 “methamphetamine”[All Fields] 11291 
2 “methamphetamine”[MeSH Terms] 8124 
3 “dextroamphetamine”[All Fields] 6971 
4 “dextroamphetamine”[MeSH Terms] 6806 
5 “amphetamine”[All Fields] 26997 
6 “amphetamine”[MeSH Terms] 18257 
7 “amphetamines”[All Fields] 8607 
8 “amphetamines”[MeSH Terms] 34894 
9 Search #1 OR #2, #3, #4, #5, #6, #7 45289 
10 Search #9 AND "abuse"[All Fields] 7533 
11 Search #9 AND “dependence”[All Fields] 2200 
12 Search #9 AND "use"[All Fields] 141 
13 Search #9 AND "disorder"[All fields] 3269 
14 Search #9 AND "Substance-Related Disorders"[MeSH Terms] 9066 
 




Table 1, continued 
15 Search #10 OR #11, #12, #13, #14 15014 
16 Search #15 AND "therapy"[All Fields] 2879 
17 Search #15 AND "therapy"[Subheading] 3377 
18 Search #15 AND "treatment"[All Fields] 4503 
19 Search #15 AND "therapeutics"[MeSH Terms] 2697 
20 Search #15 AND “therapeutics”[All Fields] 145 
21 Search #15 AND  "medication"[All Fields] 820 
22 Search #15 AND "amphetamine-related disorders/drug therapy"[MAJR] 127 
23 Search #16 OR #17, #18, #19, #20, #21, #22 7915 
24 Search #23 AND "humans"[MeSH Terms] 5749 
25 Search #23 AND English[lang] 7430 
26 Search #23 AND "adult"[MeSH Terms] 2963 
27 Search #24 AND #25, #26 2765 
 
Study Selection 
Results of the various iterations of the PubMed search strategy are presented in Table 1. The 
search included records from date of inception of PubMed to November 29, 2016. The last 
search was performed on December 2, 2016. The process of record screening and eligibility 
review is outlined in Figure 2. I identified a total of 2,765 records with the final search. I 
screened the title and abstracts of each record and excluded 2,666. I downloaded the full text of 
the remaining 99 articles and reviewed the eligibility of each for final inclusion in analysis. I 
excluded 88 articles from the final analysis. Finally, 11 articles were included in the analysis. 
References for all excluded articles and reason for exclusion can be found in the references 




The majority of excluded articles were pre-clinical studies of the effects of various 
pharmacological treatments on different aspects of methamphetamine use. Most of these studies 
were conducted in controlled human laboratory settings. Broadly, these studies fell into one or 
more of the following categories of investigation: attenuation of various effects of acute 
amphetamine exposure, enhancement of neurocognitive processes in participants with chronic 
methamphetamine exposure, changes in the choice of amphetamine dose under controlled 
conditions, or safety and/or tolerability of proposed treatments. The different pharmacological 
treatments found in these preclinical studies include naltrexone, modafinil, bupropion, diltiazem, 
clonidine, isradipine, topiramate, rivastigmine, gamma-vinyl-gamma-amminobutyric acid, 
aripiprazole, selegiline, perindopril, progesterone, risperidone, lithium, atomoxetine, varenicline, 
valproate, and cytidine-5’-diphosphate choline. 
Fourteen articles were studies included in the systematic review of agonist treatments by Bhatt et 
al.11 Five articles were previously reviewed by Brackins et al.15 Four articles were either 
republications of previously published studies or secondary analyses of previously published 
studies. Three articles did not include reduction in methamphetamine use as an outcome 
measure. Another three articles were conducted on inpatient populations. These articles were 
focused on symptom reduction and also did not include reduction in methamphetamine use as an 
outcome. One study reported on the decline in methamphetamine use in a population with 





Figure 2: Flow diagram 
Study characteristics 
The eleven studies included in the analysis examined 8 different pharmacological treatments 
among 802 participants. The characteristics of studies included in the final analysis are presented 
in Table 2.  Eight studies were published after 2011 when the previous systematic review by 
Brackins et al was done.15 Interestingly, three studies were published before 2012 but were not 
identified in that review. Most studies were conducted in the USA, although the most recent 
studies were conducted in Iran and Malaysia. One study each was conducted in Russia and 
Sweden. Study size was small in all trials, ranging from 31 to 140 participants. 
Interventions included buprenorphine, citocoline, topiramate, mirtazapine, N-acetyl-cysteine 
(NAC), naltrexone, aripiprazole, and a combination of flumazenil/gabapentin/hydroxyzine. One 
study each used buprenorphine, citocoline, topiramate, and mirtazapine as interventions. One 
study used N-acetyl-cysteine (NAC) by itself, while another used a combination of NAC and 
Full Text Articles Excluded 
N = 88 
 
Preclinical Study = 41 
Not a RCT = 17 
Agonist Treatment = 14 
Previously Reviewed = 5 
Duplicate = 4 
Wrong outcome = 3 
Wrong setting = 3 
Wrong population = 1 
 
Duplicates Removed 
N = 0 
Title and Abstracts Screened 
N = 2765 
 
Full Text Articles Assessed for 
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Studies Included for Qualitative 
Synthesis 
N = 11 
Records Excluded After Initial 
Review 
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naltrexone. Two studies used aripiprazole. Three studies used naltrexone: one in combination 
with NAC, one as an oral pill, and another as an implant. All studies used inactive placebos for 
controls, including one study with a placebo implant. 
All 11 studies reported that methamphetamine use was measured using urine drug screens 
(UDS), but two of the studies did not report the results of these measurements. Three studies did 
not report study retention as an outcome measure, and did not provide enough data to calculate a 
statistical comparison of numbers remaining in each arm at the end of the study. Two studies 
reported that they measured scores for methamphetamine craving, but did not present the results. 




Table 2: Characteristics and results of included studies 
Author Yr Design N Dura-
tion 
Participants Intervention UDS Retention Craving Int Val Ext 
Val 
Salehi et al 2015  RCT 40  16 
weeks 
All men referred to 


































patients referred to 
tertiary care in Iran 
















2013 RCT 49 8 weeks All participants 
had been included 
in a 2-week open 
label trial of 
aripiprazole 
immediately prior 


























































































NR Poor Poor 
Elkashef et 
al 
2012 RCT 140 13 
weeks 
Patients at multiple 
substance abuse 









39 in interven 
retained to 
end of study 











2012 RCT 100 10 
weeks 
Treatment seeking 
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Ling et al 2012 RCT 120 108 
days 
Treatment seeking 












57 days for 
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2011 RCT 60 12 
weeks 
Treatment seeking 
MSM with high 
risk sexual 
behavior recruited 










NR NR Good Poor 
Grant et al 2010 RCT 31 8 weeks Treatment seeking 
patients recruited 
from the 










































































































































Salehi et al ? ? - - + - - + ? P P 
Mousavi et 
al 
- - ? ? ? - + + - P P 
Sulaiman 
et al 
+ + - - + + - - - P P 
Coffin et 
al 
+ + + + + + - + - F F 
Brown and 
Gabrielson 
? ? + + + + - + - P P 
Elkashef et 
al 
+ ? ? ? + ? - + + F G 
Tiihonen 
et al 
+ + + - + - - + + F P 
Ling et al + + + + + + - + + G F 
Colfax et 
al 
+ + + + + + + + + G P 




? + + + + + - + - P P 




The results of the analysis of the risk of bias and overall internal validity are presented in Figure 
3 above. Only 2 studies (Ling et al and Colfax et al) were judged to have good internal validity. 
Four studies were judged to have fair internal validity, and the remaining 5 studies had poor 
internal validity. The most common domain for a high risk of bias was attrition bias due to 
differential loss of participants between the arms, overall high numbers of drop outs, and/or no 
presented analysis of the drop outs. The second most common domain with a high risk of bias 
was the “other” category, in all but one case because of imbalance at baseline between arms of 
the study or lack of reporting on baseline characteristics. Full information including supporting 
comments on the risks of bias for each study can be found in Appendix B.  
Results of individual studies 
The results from each study for the main outcome measures of interest to this review can be 
found in Table 2. Two studies (Colfax et al20 and Jarayam-Lindstrom et al21) reported significant 
improvements in UDS results for mirtazapine and naltrexone, respectively. Three studies 
(Sulaiman et al22, Brown and Gabrielson23, and Tiihonen et al24) reported significant 
improvements in retention for aripiprazole, citocoline, and naltrexone implant respectively. Four 
studies (Salehi et al, Moussavi et al, Sulaiman et al, and Jarayam-Lindstrom et al) reported 
significant improvements in craving scores for buprenorphine, NAC, aripiprazole, and 
naltrexone respectively. 
Salehi et al conducted an RCT of buprenorphine 6mg among men in Iran with methamphetamine 
dependence referred to an addiction treatment center and reported a significant decrease in 
methamphetamine craving as measured by an adapted version of the Cocaine Craving Brief 
Questionnaire (CCQ-brief) (p<0.001 by ANCOVA). They also reported the results of UDS at 




through 6, but did not report an overall measure of UDS positivity. They did not report on the 
prevalence of opioid use in the sample population, which significantly limits the interpretability 
of the results. Most importantly, the study reported 20 participants in each arm and 100% 
completion rate, but the numbers given for the first week craving score indicated that there were 
actually 31 participants in the control group and 23 in the intervention group at the beginning of 
the study. No reasons or explanation for the discrepancy were given and I judged it to have poor 
internal validity as a result. 
Mousavi et al conducted a randomized cross-over study in 32 men and women in Iran with 
methamphetamine dependence referred to a tertiary care center using N-acetyl-cysteine (NAC) 
1200mg and reported a significant decrease in methamphetamine craving as determined by 
CCQ-brief scores (p<0.001 ANOVA). However, the results were analyzed only among 
participants who finished the study, and 28% of the participants were lost to follow-up. 
Moreover, I judged it to have high risk of reporting bias as the study methods stated that UDS 
were done at each visit, but no results from the UDS were reported. 
Sulaiman et al reported on an RCT of aripiprazole 10mg in 49 participants in Malaysia with 
methamphetamine dependence and a history of psychotic symptoms and reported no significant 
difference in UDS results (p = 0.173 GEE). They did report a significant reduction in craving as 
measured by the Brief Substance Craving Scale (p = 0.015 MMRM) and a significant 
improvement in retention 48.7 days (SD 4.0) in intervention arm versus 37.1 days (SD 5.0) in the 
control arm (p < 0.05 Kaplan-Meier survival analysis). However, the validity of these results is 
questionable as all participants in the trial had previously participated in an open label un-




Coffin et al performed an RCT of aripiprazole 20mg in 90 men and women with 
methamphetamine dependence recruited from the general community in San Francisco. They 
reported no significant difference in positive UDS (RR 0.88 p = 0.41), craving, as measured by a 
visual analog scale (p = 0.38) or retention, defined as number of completed weekly counseling 
sessions (76% in intervention versus 80% in control, p = 0.11). There were twice as many 
participants in the intervention group (10) that dropped out of the study, and the reasons for drop 
out was not reported. 
Brown and Gabrielson reported on an RCT of citicoline 2000mg in 60 men and women in the 
USA with methamphetamine use and either bipolar depression or major depressive disorder. 
They reported no significant difference in UDS results (RR 1.09 favoring control p = 0.23), 
although they did report significantly improved retention in the intervention arm (p = 0.02 
Kaplan-Meier). The results, however, were analyzed only among the 48 of 60 participants who 
returned for follow-up after randomization. 
Elkashef et al conducted an RCT of topiramate 200mg in 140 men and women with 
methamphetamine dependence in the USA. They found no significant difference in UDS (p = 
0.13 GEE), craving by BSCS (p = 0.09), or retention defined as completion of study (p = 0.72). 
The study was limited by a high loss of participants; only 55% completed the study. 
Tiihonen et al performed an RCT of a naltrexone implant compared to a placebo implant in 100 
men and women with both amphetamine and opioid dependence. They found no significant 
difference in UDS results (p = 0.09) or craving (analysis not reported), but did report a 
significant improvement in retention in the intervention group measured by percent present at 
study end (52% in intervention versus 28% in control, p = 0.01). A significant limitation to this 




detected by experienced opioid users in a dual opioid and methamphetamine population makes it 
unclear if the results are due to changes in opioid use, un-blinding, or a true effect on 
methamphetamine use. 
Ling et al conducted an RCT of the PROMETA™ protocol (a proprietary protocol involving 
flumazenil 2mg IV, gabapentin 1200mg, and hydroxyzine 50mg) in 120 treatment seeking men 
and women with methamphetamine dependence. They found no significant differences in UDS 
(p = 0.28), craving (statistics not reported), or retention in treatment when adjusted for a baseline 
imbalance in age between groups (p = 0.30). As in other studies, there was a high rate of attrition 
in both groups (41.1% in intervention arm, and 30.9% in control arm). 
Colfax et al conducted an RCT of mirtazapine 30mg in 60 MSM with methamphetamine 
dependence and high risk sexual practices. They reported a significant difference in UDS 
favoring the intervention (RR 0.57 CI 0.35-0.93). They did not report on retention or craving. I 
found no significant sources of bias affecting internal validity. However, because 
methamphetamine use was associated with sex in this population it is possible that the results 
were due not to a direct effect of mirtazapine on methamphetamine use, but rather to a reduction 
in high risk sex that was accompanied by methamphetamine use among the study participants. 
Grant et al performed an RCT of NAC 2400mg plus naltrexone 200mg in 31 men and women 
with methamphetamine dependence. They reported no significant difference in UDS (p = 0.547), 
craving as measured by the Penn Craving Scale (p = 0.106), or retention defined as study 
completion (p = 0.337). The study had a high rate of attrition, with only 17 of 31 (54%) 
completing all five visits, 8 of whom dropped out immediately after randomization and were not 




Jayaram-Lindstrom et al conducted an RCT of naltrexone 50mg in 80 men and women in 
Sweden with amphetamine dependence. They reported a significant difference in UDS favoring 
the intervention arm with 65.2% negative UDS versus 47.7% in control arm (p < 0.05). They 
also reported a significant difference in craving scores (p < 0.05), although the actual numbers 
were not reported. They did not analyze retention in treatment, but from the data they did 
present, 72.5% in the intervention arm finished the study as did 65% in the control arm. There 
was a high attrition rate, with only 55 patients finishing the study, and there was a significant 
baseline difference between groups in the severity of amphetamine use (31 days used in the 
previous 12 weeks in the intervention group versus 27 in the control). An important caveat to this 
study is that the main form of amphetamine used by participants in the study was a mixture of 
dextro- and levo-amphetamine, not methamphetamine, and that 47.5% of participants carried a 
diagnosis of ADHD. 
Synthesis of results 
I found no study with both good internal and good external validity. The overall level of internal 
validity within studies was limited by small study size and high numbers of drop outs. 
Comparison between studies was often not possible because outcome measures were 
inconsistently measured, defined and reported. Because of this, it is difficult to comment on 
potential reasons for differences between the studies.  
When considered by level of internal validity, only studies with good or fair internal validity 
reported significant improvements on the objective measure of UDS, whereas a higher 






Internal Validity N 
Benefit on  
UDS (n) % 
Benefit for  
Retention (n) % 
Benefit for  
Craving (n) % 
Any  
Benefit (n) % 
Poor 5 0 0% 2 40% 3 60% 4 80% 
Fair 4 1 25% 1 25% 1 25% 2 50% 
Good 2 1 50% 0 0% 0 0% 1 50% 
 
The 2 studies that reported significant improvement in UDS used different medications, 
mirtazapine and naltrexone. Both had higher percentages of participants retained to the end of 
the study than the average among analyzed studies. Colfax et al had an impressive retention rate 
of 93%, while Jayaram-Lindstrom et al had a completion rate of 69%. They also both examined 
the treatment in populations distinct from the general population of methamphetamine use 
disorder. Colfax et al included only MSM with high risk sexual practices, while Jayaram-
Lindstrom et al included participants with amphetamine dependence who used mostly non-
methamphetamine. 
Risk of bias across studies 
I did not conduct an assessment of the risk of bias across studies. 
Discussion 
Summary of evidence 
I found no evidence to support a pharmacological treatment of methamphetamine use disorder in 
the general outpatient US population. Specifically, I did not find evidence supporting the use of 
buprenorphine, citocoline, topiramate, mirtazapine, N-acetyl-cysteine (NAC), naltrexone, 




The results of this review do not alter the conclusions of the other 2 published systematic reviews 
on this topic, which also found no evidence for a particular pharmacological treatment. Bhatt et 
al systematically reviewed and meta-analyzed RCTs on modafinil, bupropion, 
dextroamphetamine, and methylphenidate. Brackins et al systematically reviewed RCTs on 
sertraline, bupropion, mirtazapine, modafinil, dexamphetamine, ondansetron, risperidone, 
baclofen, gabapentin, and aripiprazole. 
I compared the list of pharmacological treatments studied in clinical RCTs to treatments 
examined in the pre-clinical studies and identified 12 pharmacological agents that have not been 
evaluated in a clinical trial for the treatment of methamphetamine use disorder. These include 
diltiazem, clonidine, isradipine, rivastigmine, gamma-vinyl-gamma-amminobutyric acid 
(vigabatrin), selegiline, perindopril, progesterone, lithium, atomoxetine, varenicline, and 
valproate. 
Limitations of the data 
A major limitation of the reviewed literature is that the sizes of reported studies are likely to be 
inadequate for detecting significant treatment effects. This is compounded by the fact that almost 
all studies, with the exception of the mirtazapine study among MSM by Colfax et al,  suffered 
large numbers of drop outs.20 The high percentage of drop outs in these studies is likely an 
inevitable complication of trials for substance use disorders. High proportions of drop outs in 
these studies means that the studies are more likely to underestimate the true effect size. Larger 
sample sizes in anticipation of high attrition rates may help to minimize this bias by providing 
greater power to detect significant differences. 
Likewise, adherence to treatment is a major problem in this population, significantly limiting the 




injectable or implant formulations where possible. Long acting formulations of naltrexone, 
buprenorphine and several antipsychotics are now or will soon be available. Use of these 
formulations would significantly improve the reliability of the results. Barring this, use of 
biomarker measures of adherence such as blood level monitoring or measurement of urine 
riboflavin incorporated into study drugs could help to pinpoint whether adherence is, in fact, a 
major reason for non-significant findings. 
Several reviews and studies used “abstinence” from MA use as a main outcome. However, the 
definition of abstinence varied between studies, not all studies reported it as an outcome, and the 
clinical significance of subjectively defined “abstinence” vs overall reduction in MA use is not 
clear. A more useful and comparable approach for future studies would be either to adopt a 
standard definition of “abstinence” in the context of short term trials (the creation of which is 
limited by the lack of evidence on what constitutes a significant measure), or report all trials 
using the same measure of percentage of positive UDS. This would also limit the risk of 
selective reporting bias, as it is not always clear if the definitions of “positive week” or 
“abstinence” could have been manipulated to yield more significant results. 
Measurement bias is a significant concern. Some studies in this review measured UDS only once 
every 2 weeks, while others performed UDS 3 times a week. The risk of not detecting significant 
differences is already higher because of attrition bias, which is very difficult to change, and 
increasing and standardizing the frequency of UDS in studies is an obvious and achievable way 
of improving the internal validity of future trials. A related issue is, in effect, the uncertainty 
about what might otherwise be thought of as the interventions’ Minimal Clinically Significant 
Difference:  there appears to be no agreed upon standard by which to judge the clinical 




positive across all weeks, while others performed analyses on varying periods of time with 
negative UDS. 
Limitations of this review 
A significant limitation of this review is that it was conducted by a single investigator. Analyses 
of the internal and external validity of studies will usually contain some element of subjectivity. 
It is possible that some of the findings of this review, particularly judgements about the various 
risks of bias within studies and generalizability of findings, would be slightly different if done 
independently by multiple researchers. If possible, having multiple researchers conduct a future 
review would strengthen the internal validity of the review itself. 
I did not conduct an assessment of possible publication bias. However, I believe it is unlikely 
that any un-published studies would change the conclusion of this review that no 
pharmacological treatments for methamphetamine use disorder have been proven to be effective. 
Publication bias tends toward publishing of positive, rather than negative results. It is more likely 
that there are un-published negative studies of treatments. Nevertheless, the knowledge of 
negative results would help to move the field forward, and a future review would be strengthened 
by attempting to identify which treatments have been studied but not published. Potential 
strategies for addressing this in a future review include searching trial registries, searching for 
relevant conference proceedings and meeting abstracts, and consulting with experts and study 
authors to identify other relevant studies that may not have been published. 
Likewise, there may have been relevant published studies that were not identified by this review 
because of its reliance on searching within a single database, PubMed. A future review would be 
enhanced by searching multiple databases. Furthermore, I conducted a single final search of 




identified by the use of a looping search strategy that repeated the iterations of the search process 
with slight variations to keep all previously identified studies while potentially including new 
relevant studies. 
Finally, while the goal of this systematic review was to fill in the gap between the two previously 
published systematic reviews, the usefulness of this review in guiding future research is limited 
by the fact that the many pertinent studies of agonist treatments were left out of the analysis. It is 
possible that a synthesis of all pertinent studies including agonist treatments would have yielded 
different conclusions about the various risks of bias, the potential reasons for non-significant 
results, and the potential approach to minimizing these issues in future research.  
Conclusion 
Several studies reported positive results, but were limited by poor internal or external validity 
and no evidence was found to support treatment of methamphetamine use disorder with a 
specific medication in the general outpatient population, which had also been found in 2 other 
systematic reviews of a distinct set of studies. There is a pressing need for more research in this 
field. Future trials should use consistent outcome measures and address possible power issues 
caused by high attrition. 
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Item Judgement Description 
1. Random sequence 
generation (selection 
bias) 
Low risk  The investigators describe a random component in 
the sequence generation process such as: random 
number table; computerized random number 
generator; coin tossing; shuffling cards or envelopes; 
throwing dice; drawing of lots; minimization 
 High risk The investigators describe a non-random component 
in the sequence generation process such as: odd or 
even date of birth; date (or day) of admission; 
hospital or clinic record number; alternation; 
judgement of the clinician; results of a laboratory test 
or a series of tests; availability of the intervention  
 Unclear risk  Insufficient information about the sequence 
generation process to permit judgement of low or 




Low risk  Investigators enrolling participants could not foresee 
assignment because 1 of the following, or an 
equivalent method, was used to conceal allocation: 
central allocation (including telephone, web-based, 
and pharmacy- controlled, randomization); 
sequentially numbered drug containers of identical 
appearance; sequentially numbered, opaque, sealed 
envelopes  
 High risk Investigators enrolling participants could possibly 
foresee assignments because 1 of the following 
methods was used: open random allocation schedule 
(e.g. a list of random numbers); assignment 
envelopes without appropriate safeguards (e.g. if 
envelopes were unsealed or non-opaque or not 
sequentially numbered); alternation or rotation; date 
of birth; case record number; any other explicitly 
unconcealed procedure  
 Unclear risk  Insufficient information to permit judgement of low 
or high risk. This is usually the case if the method of 
concealment is not described or not described in 








Objective outcomes  
Low risk  No blinding or incomplete blinding, but the review 
authors judge that the outcome is not likely to be 
influenced by lack of blinding;  
Blinding of participants and key study personnel 
ensured, and unlikely that the blinding could have 
been broken  
 High risk No blinding or incomplete blinding, and the outcome 
is likely to be influenced by lack of blinding; 
Blinding of key study participants and personnel 
attempted, but likely that the blinding could have 
been broken, and the outcome is likely to be 
influenced by lack of blinding 
 Unclear risk  Insufficient information to permit judgement of low 
or high risk  





Low risk  Blinding of participants and providers ensured and 
unlikely that the blinding could have been broken  
 High risk No blinding or incomplete blinding, and the outcome 
is likely to be influenced by lack of blinding; 
Blinding of key study participants and personnel 
attempted, but likely that the blinding could have 
been broken, and the outcome is likely to be 
influenced by lack of blinding 
 Unclear risk  Insufficient information to permit judgement of low 
or high risk 
5. Blinding of outcome 
assessor (detection bias) 
Objective outcomes 
Low risk  No blinding of outcome assessment, but the review 
authors judge that the outcome measurement is not 
likely to be influenced by lack of blinding. Blinding 
of outcome assessment ensure, and unlikely that the 
blinding could have been broken. 
 High risk No blinding of outcome assessment, and the outcome 
measurement is likely to be influenced by lack of 
blinding; 
Blinding of outcome assessment, but likely that the 




measurement is likely to be influenced by lack of 
blinding  
 Unclear risk  Insufficient information to permit judgement of low 
or high risk 
6. Blinding of outcome 
assessor (detection bias) 
Subjective outcomes  
Low risk  Blinding of outcome assessment ensured, and 
unlikely that the blinding could have been broken 
 High risk No blinding of outcome assessment, and the outcome 
measurement is likely to be influenced by lack of 
blinding; 
Blinding of outcome assessment, but likely that the 
blinding could have been broken, and the outcome 
measurement is likely to be influenced by lack of 
blinding 
 Unclear risk  Insufficient information to permit judgement of low 
or high risk 
7. Incomplete outcome 
data (attrition bias) For 
all outcomes except 
retention in treatment  
Low risk  No missing outcome data; 
Reasons for missing outcome data unlikely to be 
related to true outcome (for survival data, censoring 
unlikely to introduce bias); 
Missing outcome data balanced in numbers across 
intervention groups, with similar reasons for missing 
data across groups; 
For dichotomous outcome data, the proportion of 
missing outcomes compared with observed event risk 
not enough to have a clinically relevant impact on the 
intervention effect estimate; 
For continuous outcome data, plausible effect size 
(difference in means or standardized difference in 
means) among missing outcomes not enough to have 
a clinically relevant impact on observed effect size; 
Missing data have been imputed using appropriate 
methods; 
All randomised participants are reported/analyzed in 
the group they were allocated to by randomization 
irrespective of non-adherence and co-interventions 
(intention-to-treat)  
 High risk Reason for missing outcome data likely to be related 
to true outcome, with either imbalance in numbers or 




For dichotomous outcome data, the proportion of 
missing outcomes compared with observed event risk 
enough to induce clinically relevant bias in 
intervention effect estimate; 
For continuous outcome data, plausible effect size 
(difference in means or standardized difference in 
means) among missing outcomes enough to induce 
clinically relevant bias in observed effect size;  
’As-treated’ analysis done with substantial departure 
of the intervention received from that assigned at 
randomization 
 Unclear risk  Insufficient information to permit judgement of low 
or high risk (e.g. number randomised not stated, no 
reasons for missing data provided; number of 
dropouts not reported for each group)  
8. Selective reporting 
(reporting bias)  
Low risk  The study protocol is available and all of the study’s 
pre-specified (primary and secondary) outcomes that 
are of interest in the review have been reported in the 
pre-specified way; 
The study protocol is not available but it is clear that 
the published reports include all expected outcomes, 
including those that were pre-specified (convincing 
text of this nature may be uncommon) 
 High risk Not all of the study’s pre-specified primary outcomes 
have been reported; 1 or more primary outcomes is 
reported using measurements, analysis methods or 
subsets of the data (e.g. subscales) that were not pre-
specified; 1 or more reported primary outcomes were 
not pre-specified (unless clear justification for their 
reporting is provided, such as an unexpected adverse 
effect);  
1 or more outcomes of interest in the review are 
reported incompletely so that they cannot be entered 
in a meta-analysis; 
The study report fails to include results for a key 
outcome that would be expected to have been 
reported for such a study 
 Unclear risk  Insufficient information to permit judgement of low 




9. Other bias  Low risk  The study appears to be free from other sources of 
bias. 
 High risk There is at least 1 important risk of bias. For 
example, the study: 
Had a potential source of bias related to the specific 
study design used; Stopped early due to some data-
dependent process (including a formal- stopping 
rule); 
Had extreme baseline imbalance; 
Has been claimed to have been fraudulent; or 
Had some other problem. 
 Unclear risk  There may be a risk of bias, but there is either: 
Insufficient information to assess whether an 
important risk of bias exists; or 
Insufficient rationale or evidence that an identified 







Author Salehi et al 
Year 2015 
  {Salehi:2015fe} 
1. Random Sequence Generation 
(Selection Bias) Unclear risk 
1. Support 
Quote: "The 40 selected individuals were allocated 
into 2 groups of either intervention or placebo using a 
random allocation method (20 patients in each 
group)." 
2. Allocation concealment (selection 
bias) Unclear risk 
2. Support Concealment is not described 
3. Blinding of participants and 
providers (performance bias) 
Objective Outcomes High risk 
3. Support 
Providers are not stated as being blinded. Also, 
buprenorphine has typical side effects and withdrawal 
syndrome that would likely alert patients to active 
drug. 
4. Blinding of participants and 
providers (performance bias) 
Subjective Outcomes High risk 
4. Support 
Providers are not stated as being blinded. Also, 
buprenorphine has characteristic noticeable effects 
and it is likely patients were aware of allocation 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support 
Although assessors were not stated as being blinded, 
unlikely to affect results of urine drug test. 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) High risk 
6. Support 
Assessors not stated as being blinded. Also, 
participants likely aware of allocation because of 
buprenorphine effects. 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
No patients were reported as withdrawn. However, 
Table 1 shows n of 31 in placebo group and 23 in 
intervention group at baseline. If this represents 
number of patients in each arm at the beginning of the 
study, there were 11 lost in the placebo group and 3 in 




significant risk for attrition bias in such a small 
sample. 
8. Selective reporting (reporting bias) Low risk 
8. Support 
Study protocol wasn't available, but urine drug tests 
and craving measurement are expected outcomes for 
this type of study 
9. Other bias Unclear 
9. Support 
Baseline characteristics reported as statistically equal 
between groups, but no information given 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Poor 
11. External Validity Poor 
11. Support 
Because baseline psychiatric and substance use 
comorbidities were not reported and the criteria for 
"severe psychiatric disorder" was not defined, it is 
difficult to know how applicable these results are to 
methamphetamine users in the US as many patients 
have these comorbidities. 
Study 
description 
and funding Author Salehi et al 
  Year 2015 
    {Salehi:2015fe} 
  Type RCT 
  Country Iran 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? No 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation 
Unclear, "random allocation 
method" with 20 patients ending up 
in each group 




Patients blinded, unclear if 
clinicians/therapists/assessors 
blinded or not 
  Design: single site/multiple Single 
  Study duration 16 weeks 
  Number of participants 40 
  
Handling of dropouts (ITT or per 
protocol) Not stated 
  
Instruments used to assess study 
outcomes 
1. Cocaine craving brief 
questionnaire (CCQ-Brief) adapted 
for meth 2. UDS every 2 weeks 
Participants Source Population 
Men ages 18-40 referred to 




  Inclusion Criteria Inclusion criteria not stated 
  Exclusion Criteria 
Excluded severe mood disorder 
A1:AO4 not defined), suicidal 
thoughts, psychosis, unstable 
medical conditions (not defined), 
and intolerable complications from 
medications or drug use (not 
defined) 
  Sex (% male/female) 0 
  Age (mean, SD) 31.8 (5.0) and 29.6 (5.5) 
  
Ethnicity (%white, % African 
American, % other) NR 
  Employment Status NR 
  Frequency of MA use NR 
  Years of MA use NR 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) NR 
  
Comorbid disorders (% with 
comorbid psychiatric disorders) NR 
  Name of drug buprenorphine 
  Dose 6mg 
  Control Sublingual placebo visually similar 
  Adherence Not reported, unclear if measured 
  Adjunct interventions All subjects in Matrix model 
Outcomes 
Methamphetamine use as determined 
by UDS  
UDS results presented by visit. 
Reported that UDS significantly less 
likely to be positive at third through 
sixth visit in intervention group 
  Self-reported meth use NR 
  Methamphetamine craving 
Significantly decreased p<0.001 
ANCOVA 
  Retention in Treatment NR 
  
Number of patients who finished 
study 40 
  Reason for drop outs NR 
  Clinical Global Impression score NR 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  











Author Mousavi et al 
Year 2015 
  {Mousavi:2015tm} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support Random number tables 
2. Allocation concealment (selection 
bias) Low risk 
2. Support Randomization done by 3rd party 
3. Blinding of participants and 
providers (performance bias) Objective 
Outcomes Unclear risk 
3. Support Results of objective UDS not given 
4. Blinding of participants and 
providers (performance bias) Subjective 
Outcomes Unclear risk 
4. Support 
Not stated if treatment providers were blinded, 
which could have affected elements of care leading 
to lower scores.  
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Unclear risk 
5. Support Results of objective UDS not given 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support Assessors were blinded to allocation 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
Results analyzed only among participants finishing 
study, with 9 of 32 (28%) of participants lost to 
follow-up. 
8. Selective reporting (reporting bias) High risk 
8. Support 
Only craving score and side effect outcomes are 
reported, whereas UDS  and self-report of MA use 
were both planned but not reported 
9. Other bias Low risk 
9. Support 
There was an apparent period effect, likely related 
to increased length of adjunct treatment. However, 
the period effect would be expected to bias toward 
the null, rather than for a positive effect as reported. 




bias toward no treatment effect, opposite of the 
reported results 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Poor 
11. External Validity Poor 
11. Support 
Limited applicability to outpatient US population as 
study done in Iran and patients with psychiatric and 
other drug comorbidities excluded from study. 
Study 
description and 
funding Author Mousavi et al 
  Year 2015 
    {Mousavi:2015tm} 
  Type Randomized crossover 
  Country Iran 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? NR 
  
Study funding (pharmaceutical 
company yes/no) NR 
Methods Sequence Generation Tables of random numbers 
  Allocation Concealment 





Assessors of CCQ- brief score 
were blinded to allocation. 
Patients blinded to allocation. 
Unclear if treatment providers 
were blinded. 
  Design: single site/multiple Single 
  Study duration Two 4 week sessions 
  Number of participants 32 
  
Handling of dropouts (ITT or per 
protocol) Analyzed per protocol 
  
Instruments used to assess study 
outcomes 
1. Self report days of MA use 2. 
Weekly UDS 3. Side effect report 
4. Cocaine craving brief 
questionnaire (CCQ-Brief) 
adapted for meth 
Participants Source Population 
Treatment seeking meth 
dependent patients referred to 
psychiatric ER and hospital 
  Inclusion Criteria 
Age 18-65, DSM-IV diagnosis of 
methamphetamine dependency, 
willing/able to comply with study 
and give informed consent 
  Exclusion Criteria 
Any serious medical condition, 




inadequate contraception, current 
SI, previous treatment with NAC, 
abnormal LFT's, history of 
asthma or seizure, dependence on 
any substance other than meth or 
nicotine, psychiatric disorders 
requiring mood stabilizers 
antidepressants or antipsychotics 
  Sex (% male/female) 82.6% male, 17.4% female 
  Age (mean, SD) 29.21 (4.93) 
  
Ethnicity (%white, % African 
American, % other) NR 
  Employment Status 
26% employed in Group A, 
44.4% employed in Group B 
  Frequency of MA use NR 
  Years of MA use NR 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) 0%, excluded from study 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
NR, patients on psychiatric drugs 
excluded from study 
  Name of drug NAC 
  Dose 1200mg 
  Control 
Placebo controlled crossover 
study, given in same packaging as 
intervention 
  Adherence 
Measured by review of drug 
blister packets 
  Adjunct interventions 
Matrix model 60 minute once a 
week group sessions 
Outcomes 
Methamphetamine use as determined 
by UDS  NR 
  Self-reported meth use NR 
  Methamphetamine craving 
At end of first 4 weeks 
Intervention group 3.3 (1.1), 
placebo 5.9 (1.0). At end of 
second 4 week session 
intervention group 3.2 (0.8) 
placebo 4.5 (1.8). Significantly 
improved for intervention by 
ANOVA p<0.001 
  Retention in Treatment NR 
  Number of patients who finished study 23 
  Reason for drop outs All non-compliance 
  Clinical Global Impression score NR 




  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  





Author Sulaiman et al 
Year 2013 
  {Sulaiman:2013hi} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support Computerized randomization in blocks of 4 
2. Allocation concealment (selection 
bias) Low risk 
2. Support 
Randomization done by independent person and 
randomization code stored in an envelope accessible 
only by principle investigator in case of serious 
adverse events. It was not stated whether the code 
was accessed during the study for this purpose, but 
no serious adverse events were reported and thus 
unlikely to have occurred. 
3. Blinding of participants and 
providers (performance bias) Objective 
Outcomes High risk 
3. Support 
All subjects underwent 2 week detoxification 
treatment with aripiprazole prior to study and thus 
likely could tell they were in active treatment group. 
4. Blinding of participants and 
providers (performance bias) Subjective 
Outcomes High risk 
4. Support 
All subjects underwent 2 week detoxification 
treatment with aripiprazole prior to study and thus 
likely could tell they were in active treatment group. 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support Assessors stated as blinded to allocation 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support Assessors blinded to allocation 
7. Incomplete outcome data (attrition 





Number and reasons for attrition not given. 
Moreover, the statistical analysis used would be 
expected to bias towards the null by imputing 
random effects for missing values. 
8. Selective reporting (reporting bias) Low risk 
8. Support 
All stated and expected outcomes for this type of 
study reported 
9. Other bias Low risk 
9. Support No other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Poor 
11. External Validity Poor 
11. Support 
Unclear if results would hold in users of MA who 
do not have psychotic symptoms. 
Study 
description and 
funding Author Sulaiman et al 
  Year 2013 
    {Sulaiman:2013hi} 
  Type RCT 
  Country Malaysia 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? No 
  
Study funding (pharmaceutical 
company yes/no) NR 
Methods Sequence Generation 
Computer generated 
randomization in blocks of 4. 
  Allocation Concealment 
Assignment done by independent 
person. Randomization list kept in 
sealed envelope accessible only to 





Patients and assessors were 
blinded. Not stated if treatment 
providers were blinded. 
  Design: single site/multiple Single 
  Study duration 8 weeks 
  Number of participants 49 
  
Handling of dropouts (ITT or per 
protocol) 
ITT, all subjects randomized 
included in analysis,  analysis 
done by GEE with random 
assumption 
  
Instruments used to assess study 
outcomes 
UDS on days 7,14,28,42,56, Brief 
Substance Craving Scale BSCA, 
CGI, Positive and Negative 




Participants Source Population 
Participants in a previous 2 week 
open label trial of aripiprazole 
10mg recruited from urban 
hospital clinic setting 
  Inclusion Criteria 
age 18-60, DSM-IV diagnosis 
MA dependence, MA use at least 
1/wk for previous 3 months, h/o 
psychotic symptoms 
  Exclusion Criteria 
no other DSM-IV Axis 1 
disorders or other substance use 
disorders 
  Sex (% male/female) 95% male 
  Age (mean, SD) T 35.5 (8.5), C 32.9 (8.4) 
  
Ethnicity (%white, % African 
American, % other) 
65% Malay, 24% Chinese, 11% 
Indian 
  Employment Status 81% employed full time 
  Frequency of MA use 
At least weekly by inclusion 
criteria 
  Years of MA use T 5.5 (4.8), C 4.8 (3.6) 
  Route (injection, smoking, nasal, oral) 
injection NR, smoking 57%, nasal 
32%, oral 11%) 
  
Comorbid drug disorders (% with 
comorbid drug disorders) Excluded from study 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) Excluded from study 
  Name of drug aripiprazole 
  Dose 5-10mg 
  Control Placebo 
  Adherence NR 
  Adjunct interventions 
No behavioral treatments. Some 
additional medication treatments 
including lorazepam, zolpidem 
and escitalopram 
Outcomes 
Methamphetamine use as determined 
by UDS  
No significant difference (p 0.173 
GEE) 
  Self-reported meth use NR 
  Methamphetamine craving 
BSCS significantly decreased in T 
group (p 0.015 MMRM) 
  Retention in Treatment 
Treatment arm 48.7 days (4.0), 
Placebo arm 37.1 (5.0) p<0.05 
(Kaplan Meier) 
  Number of patients who finished study 
Number of drop outs not reported 
directly. Visual estimation from 
Kaplan-Meier curve shows a 
survival of about 0.45 for placebo 




group which gives a total of 12 
drop outs from 37 total = 32% 
  Reason for drop outs NR 
  Clinical Global Impression score 
CGI improved in treatment arm (p 
0.014 MMRM) 
  Psychotic symptoms 
No difference in PANSS (p 0.032 
MMRM) 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events NR 
  





Author Coffin et al 
Year 2013 
  {Coffin:2013fl} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support 
1:1 random allocation sequence in blocks of 4 
generated in SAS 
2. Allocation concealment (selection bias) Low risk 
2. Support 
MEMS medication caps numbered sequentially, 
conceivably possible to guess allocation by blocks 
of 4 if medication effects were apparent, however 
given lack of evidence for patient unblinding this 
is considered unlikely 
3. Blinding of participants and providers 
(performance bias) Objective Outcomes Low risk 
3. Support 
"At study completion, participants were asked to 
guess their assignment. There was no evidence of 
unblinding: 17 (53%) in the aripiprazole arm and 
15 (47%) in the placebo arm guessed correctly 
(p=0.36)." 
4. Blinding of participants and providers 
(performance bias) Subjective Outcomes Low risk 
4. Support 
"At study completion, participants were asked to 
guess their assignment. There was no evidence of 
unblinding: 17 (53%) in the aripiprazole arm and 





5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support Unlikely to affect results of urine screens 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support 
Audio computer assisted self interview used to 
collect study data 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
There was an imbalance in drop outs by group: 10 
dropped out in intervention arm, 5 in placebo arm. 
The reasons for drop outs were not known. 
8. Selective reporting (reporting bias) Low risk 
8. Support 
All stated and expected outcomes for this type of 
study reported 
9. Other bias Low risk 
9. Support no other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Fair 
11. External Validity Fair 
11. Support 
Excluded patients with comorbid drug or 
psychiatric disorders. 
Study description 
and funding Author Coffin et al 
  Year 2013 
    {Coffin:2013fl} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? No 
  
Study funding (pharmaceutical 
company yes/no) No. NIDA. 
Methods Sequence Generation 
1:1 random allocation sequence 
in blocks of 4 generated in SAS 
  Allocation Concealment 
MEMS cap bottles numbered 
sequentially to correspond with 
allocation sequence. Allocation 
sequence available only to 




Patients and providers blinded 
with medication and placebo 
prepared by off-site pharmacist. 
  Design: single site/multiple single 
  Study duration 12 weeks 





Handling of dropouts (ITT or per 
protocol) 
ITT, all subjects randomized 
included in analysis 
  
Instruments used to assess study 
outcomes 
weekly UDS, CES-D 
depression scale, Visual 
Analog Scale for meth 
cravings, Severity of 
Dependence Scale for self 
reported MA use 
Participants Source Population 
San Francisco general 
community 
  Inclusion Criteria 
DSM-IV MA dependence, age 
18-60, MA positive urine at 
screening, no acute medical or 
psychiatric illness, no 
significant baseline laboratory 
abnormalities 
  Exclusion Criteria 
No current depression or 
bipolar disorder, psychiatric 
medication within 4 weeks, 
CD4<200 
  Sex (% male/female) 87.8% male 
  Age (mean, SD) 38.7 yrs 
  
Ethnicity (%white, % African 
American, % other) 
50%, 18.9% African American, 
16.7% Latino, 14% other 
  Employment Status 14.4% full time 
  Frequency of MA use 69% used MA 3-7 days weekly 
  Years of MA use NR 
  Route (injection, smoking, nasal, oral) 44.4% injection 
  
Comorbid drug disorders (% with 
comorbid drug disorders) excluded from study 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
excluded from study, although 
6 participants revealed 
psychiatric disorder they had 
not disclosed after the study 
  Name of drug aripiprazole 
  Dose 20mg 
  Control placebo 
  Adherence 
Evaluated by Medication Event 
Monitoring System and self-
report. By MEMS 42%, by 
self-report 74%. 
  Adjunct interventions 
Weekly counseling with 
clinical psychologist, CBT and 
MI. 
Outcomes 
Methamphetamine use as determined 
by UDS  





  Self-reported meth use 
SDS score decrease not 
significant between groups 
p=0.96 
  Methamphetamine craving 
VAS score decrease not 
significant p=0.38 
  Retention in Treatment 
No completed weekly 
substance use counseling 
sessions: intervention 76%, 
placebo 80%, p=0.11 
  Number of patients who finished study 
75 (35 in treatment arm, 40 in 
placebo) = 83% 
  Reason for drop outs NR 
  Clinical Global Impression score NR 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity 
CES-D coefficient 1.47 (-.282-
5.76) p=0.5 (GEE) 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  





Author Brown and Gabrielson 
Year 2012 
  {Brown:2012dt} 
1. Random Sequence Generation 
(Selection Bias) Unclear risk 
1. Support Stated as "randomized" without further explanation 
2. Allocation concealment (selection 
bias) Unclear risk 
2. Support Concealment procedure not described 
3. Blinding of participants and providers 
(performance bias) Objective Outcomes Low risk 
3. Support Both patients and staff stated as being blinded.  
4. Blinding of participants and providers 
(performance bias) Subjective 
Outcomes Low risk 
4. Support Both patients and staff stated as being blinded 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 




6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support Both patients and staff stated as being blinded 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
12 out of 60 of randomized participants were lost to 
follow up immediately following randomization 
and were not included in analysis. Also, placebo 
arm had only 14% completion rate. 
8. Selective reporting (reporting bias) Low risk 
8. Support All stated and expected outcomes reported 
9. Other bias High risk 
9. Support 
Baseline characteristics significantly different 
between groups by age and years of meth use. Also, 
12 or 20% of the original 60 randomized were not 
included in analysis and were not included in Table 
1 of baseline characteristics. High risk that the 
groups could have become unbalanced in some 
other way. 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Poor 
11. External Validity Poor 
11. Support 
Unclear if results would be the same if population 
not limited to bipolar depression or MDD. 
Study 
description and 
funding Author Brown and Gabrielson 
  Year 2012 
    {Brown:2012dt} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? Yes. Sunovion. 
  
Study funding (pharmaceutical 
company yes/no) 
No. Stanley Medical Research 
Institute. 
Methods Sequence Generation Not described. "Randomized" 




Patients and all staff with patient 
contact blinded to treatment 
group. 
  Design: single site/multiple single 
  Study duration 12 weeks 
  Number of participants 60 
  
Handling of dropouts (ITT or per 
protocol) 
Analyzed by group at week 1 




not return for at least one visit 
after randomization 
  
Instruments used to assess study 
outcomes 
twice weekly UDS, Inventory of 
Depressive Symptomatology 
Clinician Version IDS-C 
Participants Source Population Not described 
  Inclusion Criteria 
age 18-70, currently depressed 
with bipolar I/II/NOS, MDD with 
symptoms of at least 4 weeks, 
meth dependence with MA use in 
the 14 days prior 
  Exclusion Criteria 
psychotropic medication changes 
14 days prior, pregnant or 
nursing, current citocoline, active 
SI/HI with plan and intent, 
cognitive impairment interfering 
with informed consent, 
incarceration, current severe or 
life threatening medical 
conditions 
  Sex (% male/female) male 54% 
  Age (mean, SD) 
41.6 (9.9) in treatment group, 
34.0 (7.3) placebo 
  
Ethnicity (%white, % African 
American, % other) 
77% white, 0% African 
American, 19% Hispanic, 4% 
other 
  Employment Status NR 
  Frequency of MA use 
Days used in last 14 days: 8(4.4) 
in intervention group, 6(3.5) in 
placebo 
  Years of MA use 
15.7 years (9.8) intervention, 9.1 
(8.0) placebo 
  Route (injection, smoking, nasal, oral) 
Smoked 60.7% intervention, 75% 
placebo; oral 3 (10.7%) 
intervention, 1 (5%) placebo; IV 
4 (14.3%) intervention, 2 (10%) 
placebo; multiple 4 (14.3%) 
intervention, 2 (10%) placebo 
  
Comorbid drug disorders (% with 
comorbid drug disorders) NR 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
All had depressed bipolar or 
MDD by inclusion criteria.  
  Name of drug citicoline 
  Dose 2000mg 
  Control placebo 




  Adjunct interventions NR 
Outcomes 
Methamphetamine use as determined 
by UDS  
No significant difference in 
changes in meth use, at exit 60% 
positive in intervention and 55% 
in placebo p=0.23. RR calculated 
from published numbers = 1.09 
  Self-reported meth use 
Stated as decreased in both 
groups but no numbers given 
  Methamphetamine craving NR 
  Retention in Treatment 
Longer survival in treatment in 
citicoline group p = 0.02 Kaplan-
Meier 
  Number of patients who finished study 
"Completion rates" stated as 41% 
in intervention, 14% placebo 
p=0.02. Note that adding up n's 
given for reason for drop outs 
adds up to 24 drop outs in 
placebo arm and 20 in 
intervention arm. 
  Reason for drop outs 
19 lost to follow up, 2 moved out 
of area, 1 entered inpatient drug 
rehab, 1 for transportation 
problems, 1 for adverse event. In 
the intervention group 14 lost to 
follow up, 1 moved out of area, 1 
entered inpatient drug rehab, 1 
for transportation problems, 1 for 
stressors at home, and 1 on 
advice of probation officer 
  Clinical Global Impression score NR 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity 
Baseline to exit change in IDS-C 
scores "significantly greater" in 
intervention compared to placebo 
(38.8 to 26.2 citicoline, 37.8 to 
33.1 placebo) F(1.31)=4.2 
p=0.05 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 1 
  








Author Elkashef et al 
Year 2012 
  {Elkashef:2012he} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support 
Adaptive randomization with no significant baseline 
differences 
2. Allocation concealment (selection 
bias) Unclear risk 
2. Support Not described 
3. Blinding of participants and 
providers (performance bias) Objective 
Outcomes Unclear risk 
3. Support 
Blinding not described and possible that typical 
effects of topiramate could have resulted in 
unblinding 
4. Blinding of participants and 
providers (performance bias) 
Subjective Outcomes Unclear risk 
4. Support 
Blinding not described and possible that typical 
effects of topiramate could have resulted in 
unblinding 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support 
Blinding not described, but unlikely that UDS 
would be affected 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Unclear risk 
6. Support Blinding not described 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
High rate of attrition could have obscured any true 
effects of the intervention. 
8. Selective reporting (reporting bias) Low risk 
8. Support 
All stated and expected outcomes for this type of 
study reported 
9. Other bias Low risk 
9. Support No other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Fair 
11. External Validity Good 
11. Support 
Did not report on baseline comorbid drug and 
psychiatric disorders, but importantly did not 






funding Author Elkashef et al 
  Year 2012 
    {Elkashef:2012he} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? Yes 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation 
adaptive randomization in 1:1 
ratio for intervention:placebo also 
balanced for site and positive or 
negative MA use within 7 days 
before randomization 




Stated as "double blind", no 
further description given 
  Design: single site/multiple Multiple (8) 
  Study duration 13 weeks 
  Number of participants 140 
  
Handling of dropouts (ITT or per 
protocol) 
ITT, no randomized participants 
excluded from analysis 
  
Instruments used to assess study 
outcomes 
UDS 3/wk, CGI, BSCS, 
Addiction Severity Index-Lite 
(ASI-Lite), Montgomery 
Depression Rating Scale 
Participants Source Population 
Patients at multiple substance 
abuse treatment centers 
  Inclusion Criteria 
DSM-IV diagnosed MA 
dependence, 18 years or older, at 
least 1 baseline positive MA urine 
screens, at least 4 urine specimens 
given during intake/baseline 
assessment 
  Exclusion Criteria 
serious medical illness, 
psychiatric conditions requiring 
ongoing medication, pregnancy or 
lactation, nephrolithiasis or renal 
impairment, court-mandated drug 
abuse treatment 
  Sex (% male/female) 
63.6% male (59.4% intervention, 
63.6% placebo) 
  Age (mean, SD) 






Ethnicity (%white, % African 
American, % other) 
82.9% white overall (85.5% 
intervention, 80.3% placebo), 
2.1% African American overall (3 
in placebo, 0 in intervention), 
1.4% Asian (1 each), 12.9% other 
overall (13.2% intervention, 
14.1% placebo) 
  Employment Status 
43.6% full time (46.4% 
intervention, 40.9% placebo) 
  Frequency of MA use 
self-report of MA use in last 30 
days mean 21.3 (8.39) overall, 
21.2 in intervention, 21.4 in 
placebo 
  Years of MA use NR 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) 
Some participants with alcohol 
dependence as this was used to 
stratify post-hoc analysis, 
however number was not 
reported. 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) NR 
  Name of drug topiramate 
  Dose 200mg 
  Control placebo 
  Adherence 
By pill count, 69.8% for 
intervention, 67.4% in placebo, no 
significant difference.  
  Adjunct interventions 




Methamphetamine use as determined 
by UDS  
Primary outcome of % of subjects 
with negative week UDS in weeks 
6-12 showed no significant 
difference by GEE p=0.13, 
measured by median quantitative 
MA level on UDS, more in 
intervention reduced use by 25% 
or more (64.2% vs 42.3% p=0.03) 
  Self-reported meth use 
50% or more reduction in use by 
self-report greater in treatment 
arm (37.9% vs 14.3% p=0.003) 
  Methamphetamine craving 
Non-significant trend to reduced 




  Retention in Treatment 
39 in intervention and 38 in 
placebo completed through week 
13, p=0.72 
  Number of patients who finished study 
77 (55%), 39 in intervention arm 
and 38 in placebo 
  Reason for drop outs 
Most common reason was failure 
to return to the clinic (19 in 
intervention, 18 placebo), 2 in 
each group dropped out because 
of reported side effects, medical 
reasons unrelated to study (1 in 
intervention), subject requested 
discontinuation (4 in intervention, 
9 in placebo), 1 in each group 
moved from area, 2 in placebo 
group incarcerated, 1 in 
intervention group terminated by 
physician due to illness, 
administrative discharge (2 in 
intervention, 1 in placebo) 
  Clinical Global Impression score 
Improvement in CGI-O in 
intervention arm p=0.03 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity 
No significant change in 
Montgomery Depression Rating 
Scale by group 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 4 (2 in each group) 
  
Number who had serious adverse 
events 
13, 1 classified as possibly and 
one as probably related to 





Author Tiihonen et al 
Year 2012 
  {Tiihonen:2012cc} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support 
Computer generated random number list in 1:1 ratio 




2. Allocation concealment (selection 
bias) Low risk 
2. Support Prepared by otherwise un-involved investigator 
3. Blinding of participants and 
providers (performance bias) Objective 
Outcomes Low risk 
3. Support 
Regular opioid users would likely be able to detect 
if naltrexone active upon using an opioid after 
implantation of active drug. However, UDS results 
not likely to be affected. 
4. Blinding of participants and 
providers (performance bias) Subjective 
Outcomes High risk 
4. Support 
Regular opioid users would likely be able to detect 
if naltrexone active upon using an opioid after 
implantation of active drug. Report of symptoms 
and assessment by providers could be affected by 
this knowledge. 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support 
Likely detectable effects of active drug by 
participants, however UDS results unlikely to be 
affected 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) High risk 
6. Support 
Likely detectable effects of active drug by 
participants. Assessors not stated but assumed to be 
treatment providers with clinical contact with 
participants 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support 
High attrition in both study groups with 
significantly more lost in placebo arm. 
8. Selective reporting (reporting bias) Low risk 
8. Support All stated and expected outcomes reported 
9. Other bias Low risk 
9. Support no other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Fair 
11. External Validity Poor 
11. Support 
Unclear what significance this has for mainly MA 
users as study primary outcome (decrease in opioid 
and amphetamine positive UDS) driven by positive 






funding Author Tiihonen et al 
  Year 2012 
    {Tiihonen:2012cc} 
  Type RCT 
  Country Russia 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? Yes 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation 
"Computer generated random 
number list" in 1:1 ratio, not 
stated what method used to 
generate ratio 
  Allocation Concealment 
 prepared by outside investigator 





"All individuals involved with the 
clinical phase of the trial were 
blind to the intervention." 
Medication labeled according to 
randomization list 
  Design: single site/multiple single 
  Study duration 10 weeks 
  Number of participants 100 
  
Handling of dropouts (ITT or per 
protocol) 
ITT, missing urine samples 
classified as positive 
  
Instruments used to assess study 
outcomes 
UDS 1/wk, Addiction Severity 
Index, CGI, visual analog scales 
of craving for opioids and 
amphetamine 
Participants Source Population NR 
  Inclusion Criteria 
DSM-IV diagnosis of both 
amphetamine and opioid 
dependence for at least 1 year, 
age 18-50, high school or above, 
negative UDS and etoh breath 
test, no current psychotropic 
medications, one relative willing 
to participate in treatment 
monitoring, stable address, home 
telephone number, able to give 
informed consent, negative 





  Exclusion Criteria 
clinically significant cognitive 
impairment, schizophrenia, 
paranoid disorder, bipolar, seizure 
disorder, advance neurological, 
CV, renal or hepatic disease, 
active TB, current febrile illness, 
AIDS, significant laboratory 
abnormality, pregnancy, pending 
legal charges with potential 
incarceration, participation in 
another study, treatment in 
another substance abuse program 
  Sex (% male/female) 
8% female intervention, 14$% 
female placebo 
  Age (mean, SD) 
29.3 (4.38) placebo, 28.0 (4.1) 
intervention 
  
Ethnicity (%white, % African 
American, % other) NR 
  Employment Status NR 
  Frequency of MA use 
days per month 24.3 (14.35) 
placebo, 27.4 (13.5) intervention 
  Years of MA use 
5.6 (2.62) placebo, 5.6 (3.11) 
intervention 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) 
All with opioid dependence by 
inclusion criteria, alcohol use 
g/day 6.8 (10.8) placebo and 8.2 
(10.11) intervention, 30% with 
MJ in intervention group, 26% in 
placebo 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
Unclear, none on psychotropic 
medications by exclusion criteria 
  Name of drug Naltrexone implant 
  Dose 1000mg 
  Control Placebo implant 
  Adherence 
NR, assume 100% for implant 
although some patients have been 
known to remove the implant on 
their own 
  Adjunct interventions 
Two psychiatrists "provided them 
with psychological support and 
advice" at unclear intervals 
Outcomes 
Methamphetamine use as determined 
by UDS  
Non-significant, amphetamine 
free urine samples 40% 





  Self-reported meth use NR 
  Methamphetamine craving 
No significant change, numbers 
not reported 
  Retention in Treatment 
At week 10 52% in intervention, 
28% in placebo, p=0.01 
  Number of patients who finished study 40 (26 intervention, 14 placebo) 
  Reason for drop outs NR 
  Clinical Global Impression score 
Much or very much improved 
56% in intervention, 14% in 
placebo p<0.001 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS 
Heroin free UDS 52% in 
intervention vs 20% placebo 
p<0.001 
  
Number dropped out due to adverse 
events NR 
  





Author Ling et al 
Year 2012 
  {Ling:2012hy} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support urn randomization 
2. Allocation concealment (selection 
bias) Low risk 
2. Support Done by pharmacy 
3. Blinding of participants and 
providers (performance bias) 
Objective Outcomes Low risk 
3. Support 
Blinding done, low risk of unblinding given mild 
effects of study drug 
4. Blinding of participants and 
providers (performance bias) 
Subjective Outcomes Low risk 
4. Support 
Mild effects of study drugs likely not detectable. 
Also, at end of study surveys at one site found that 





5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support UDS unlikely to be affected 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support 
Unlikely that mild effects of study drugs would result 
in unblinding 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support High rate of attrition in both groups 
8. Selective reporting (reporting bias) Low risk 
8. Support All stated and expected outcomes reported 
9. Other bias Low risk 
9. Support No other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Good 
11. External Validity Fair 
11. Support 




funding Author Ling et al 
  Year 2012 
    {Ling:2012hy} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? No 
  
Study funding (pharmaceutical 
company yes/no) Yes 
Methods Sequence Generation 
Urn randomization balanced on 
gender, and severity of meth use 
(>10 days in prior 30 or less) 
  Allocation Concealment 
Unclear, "randomization 
assignment was faxed to the 
university pharmacy", unclear if 
assignment was done before faxing 
or by pharmacy 
  
Blinding of 
patients/clinicians/therapists/assessors Stated as double blind 
  Design: single site/multiple Multiple (3) 
  Study duration 108 day 
  Number of participants 120 
  
Handling of dropouts (ITT or per 
protocol) 
Modified ITT, patients lost to 




randomization were not included in 
analysis 
  
Instruments used to assess study 
outcomes 
Addiction Severity Index (ASI), 
UDS weekly, Brief Symptom 
Craving Scale (BSCS) 
Participants Source Population Treatment seeking patients 
  Inclusion Criteria 
Age 18 or older, MA abuse or 
dependence per DSM-IV, treatment 
seeking, reporting MA use on 4 of 
the last 30 days, not pregnant or 
lactating and willing to use birth 
control 
  Exclusion Criteria 
Current dependence on any 
psychoactive substance other than 
MA, alcohol, nicotine or MJ, 
needing alcohol detox, disorders 
with seizures/syncope/dementia, SI, 
uncontrolled HTN, significant heart 
disease, clinically significant 
abnormal laboratory values, benzo 
use with 15 days, AIDS, active TB, 
allergy to study medications, 
treatment with PROMETA in the 
prior 12 months 
  Sex (% male/female) 
Male 80% intervention, 75% 
control 
  Age (mean, SD) 
40.77 (7.46) intervention, 35.98 
(8.75) control 
  
Ethnicity (%white, % African 
American, % other) 
White 65.4% intervention, 55.4% 
control; Hispanic 21.8% 
intervention, 37.4% control; Black 
9.1% intervention, 5.4% control 
  Employment Status 
Full time 58.2% intervention, 
53.6% control 
  Frequency of MA use 
Mean no. of days used in past 30 
days 17.82 (9.90) intervention, 
17.13 (9.45) control 
  Years of MA use 
Mean 10.84 (8.18) intervention, 
9.66 (6.60) control 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) NR 
  
Comorbid disorders (% with comorbid 




  Name of drug 
PROMETA ™ Protocol: 
flumazenil, gabapentin and 
hydroxyzine  
  Dose 
flumazenil 2mg (days 1, 2, 3, 22, 
23), gabapentin 1200mg (to day 
40), and hydroxyzine 50mg (to day 
10) 
  Control 
saline, placebo, all participants 
including intervention group 
received hydroxyzine 
  Adherence 
58.9% in intervention group 
received all 5 infusions vs 69.1% of 
control. By pill count gabapentin 
19.31 days (out of 40) intervention 
vs 20.88 days control, p-0.51. 
  Adjunct interventions Weekly CBT 
Outcomes 
Methamphetamine use as determined 
by UDS  
No significant difference in mean 
proportion of MA negative UDS 
from screening to study end p=0.28 
  Self-reported meth use 
Mean use in last 30 days: 5.04 days 
intervention, 3.96 days control 
(p=0.64) 
  Methamphetamine craving 
No significant difference. At end of 
study 2.2 intervention and 2.4 
control on 0-4 visual analog scale. 
  Retention in Treatment 
57.21 days intervention, 74.04 days 
control, not significant when 
covaried by age (p=0.30) 
  
Number of patients who finished 
study 
Retained through day 108, 18 
(32.1%) intervention, 26 (47.3%) 
control 
  Reason for drop outs 
Intervention group: inability to 
comply with study protocol (4), 
missed 3 consecutive study visit 
(21), medical/psychological 
concern (4), withdrew consent (2), 
missed 14 scheduled visits (1), in 
controlled environment (2), lack of 
transportation (2), unable to 
locate/contact (1). Control group: 
Inability to comply with study 
protocol (2), missed 3 consecutive 
study visits (15), withdrew consent 
(3), new job (1), did not attend 14 




(3), moved (1), dropped out (1), 
unknown (2) 
  Clinical Global Impression score NR 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  





Author Colfax et al 
Year 2011 
  {Colfax:2011ix} 
1. Random Sequence Generation 
(Selection Bias) Low risk 
1. Support 1:1 random allocation sequence in blocks of 4 
2. Allocation concealment (selection 
bias) Low risk 
2. Support 
Only pharmacy and statistician had access to 
allocation and had no patient contact 
3. Blinding of participants and providers 
(performance bias) Objective Outcomes Low risk 
3. Support 
Blinding done, low risk of unblinding given mild 
effects of mirtazapine, post-study survey after 
unblinding found statistically similar numbers of 
participants guessed they were on active 
medication in both arms 
4. Blinding of participants and providers 
(performance bias) Subjective Outcomes Low risk 
4. Support Blinding done, low risk of unblinding. 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 
5. Support UDS unlikely to be affected 
6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support 
Assessment done by computer assisted audio self-
interview 
7. Incomplete outcome data (attrition 
bias) Low risk 




8. Selective reporting (reporting bias) Low risk 
8. Support All stated and expected outcomes reported 
9. Other bias Low risk 
9. Support No other obvious source of bias 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Good 
11. External Validity Poor 
11. Support 
Study done only in MSM and reported very high 
retention, indicating that this population likely 
systematically different than general MA using 
population in the US 
Study description 
and funding Author Colfax et al 
  Year 2011 
    {Colfax:2011ix} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? No 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation 
1:1 random allocations 
sequence using fixed block size 
of 4 
  Allocation Concealment 
Medications prepared by off-
site pharmacist. Allocation 
known only to pharmacist and 
statistician who had no patient 
contact. No evidence of 
unmasking, at end of study 50% 
in control guessed correctly vs 




Double blind, outcomes 
assessed by UDS or computer 
assisted self report. 
  Design: single site/multiple single 
  Study duration 12 weeks 
  Number of participants 60 
  
Handling of dropouts (ITT or per 
protocol) 
ITT, all subjects randomized 
included in analysis 
  
Instruments used to assess study 
outcomes 
UDS; audio computer assisted 
self interview for CES-D. 
Participants Source Population 
STD/HIV clinics, bars, and 
community organizations 
  Inclusion Criteria 
DSM-IV MA dependence, 




self-reported anal sex with men 
in past 3 months while using 
MA, positive MA urine, no 
acute illness, no laboratory 
abnormalities 
  Exclusion Criteria 
current major depression, 
antidepressant use in the past 4 
weeks, CD4 count below 200 
  Sex (% male/female) 100% male 
  Age (mean, SD) 
40.1 (10.1) intervention, 40.9 
(8.0) control, 40.5 (9.0) overall 
  
Ethnicity (%white, % African 
American, % other) 
62% white, 18% African 
American, 12% Latino, 8% 
other 
  Employment Status 
Full time 10% intervention, 
27% control, 18% overall 
  Frequency of MA use 
7 d/wk 20% intervention, 13% 
control, 17% overall; 3-6/wk 
43% intervention, 43% control, 
43% overall, <3/wk 37% 
intervention, 43% control, 40% 
overall 
  Years of MA use NR 
  Route (injection, smoking, nasal, oral) 
Injection 50% intervention, 
40% control, 45% overall; 
Rectal 30% intervention, 30% 
control, 30% overall; Snorted 
40% in all groups; Smoked 
83% intervention, 87% control, 
85% overall; Oral 17% for all 
  
Comorbid drug disorders (% with 
comorbid drug disorders) NR 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
None on medications. CES-D 
scores of 16.6 intervention, 16.8 
control, 16.7 overall. 
  Name of drug mirtazapine 
  Dose 30mg 
  Control matched placebo in gel capsules 
  Adherence 
48.5% for MEMS (48.3% 
intervention, 48.7% control 
p=0.82), 74.7% by self-report, 
no difference between groups 
p=0.92 
  Adjunct interventions 
30 minute weekly substance use 





Methamphetamine use as determined 
by UDS  
MA positive urine tests RR 0.57 
(0.35-0.93) p=0.02, decreased 
in intervention 73% to 44%, 
placebo 67% to 63% 
  Self-reported meth use NR 
  Methamphetamine craving NR 
  Retention in Treatment 
113/240 (94.2%) visits 
completed intervention, 
114/240 (95%) control, p>0.99 
  Number of patients who finished study 
56 (93%), 28 (93%) in 
intervention, 28 (93%) control 
  Reason for drop outs NR 
  Clinical Global Impression score NR 
  Psychotic symptoms 
1 participant with MA induced 
psychosis 
  Anxiety symptom severity NR 
  Depression symptom severity 
Mean CES-D score change -3.6 
overall, no difference between 
groups p=0.57 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  





Author Grant et al 
Year 2010 
  {Grant:2010ja} 
1. Random Sequence Generation (Selection Bias) Unclear risk 
1. Support Method of randomization not stated 
2. Allocation concealment (selection bias) Unclear risk 
2. Support Concealment is not described 
3. Blinding of participants and providers 
(performance bias) Objective Outcomes Unclear risk 
3. Support Blinding not described 
4. Blinding of participants and providers 
(performance bias) Subjective Outcomes Unclear risk 
4. Support Blinding not described 
5. Blinding of Outcome Assessor objective outcomes 
(detection bias) Unclear risk 




6. Blinding of outcome assessor subjective outcomes 
(detection bias) Unclear risk 
6. Support Blinding not described 
7. Incomplete outcome data (attrition bias) High risk 
7. Support 
High attrition and not all randomized 
participants included in analysis. 
8. Selective reporting (reporting bias) Low risk 
8. Support All expected main results reported 
9. Other bias High risk 
9. Support 
Significantly underpowered to detect 
a difference between groups 
10. Overall Judgement of Internal Validity (good, fair, 
poor) Poor 
11. External Validity Poor 
11. Support 
Unclear what relevance this has for 
general population of MA users 
Study 
description 
and funding Author Grant et al 
  Year 2010 
    {Grant:2010ja} 
  Type RCT 
  Country USA 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? Yes 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation "randomly assigned in a 1:1 fashion" 




Stated as double blind but procedure 
not described 
  Design: single site/multiple single 
  Study duration 8 weeks 
  Number of participants 31 
  
Handling of dropouts (ITT or per 
protocol) 
"Only subjects who returned for at 
least one visit after starting 
medication were included". 31 of 39 
randomized subjects included in 
analysis. Missing data analyzed by 
last observation carried forward 
  
Instruments used to assess study 
outcomes 
Penn Craving Scale, UDS, self report, 
CGI, HAM-D, HAM-A, Sheehan 
Disability Scale, Quality of Life 





Participants Source Population 
recruited via newspaper 
advertisements 
  Inclusion Criteria 
age 18-65, DMS-IV amphetamine 
dependence, MA primary form of 
amphetamine 
  Exclusion Criteria 
Unstable medical illness, current 
pregnancy or inadequate 
contraception, thoughts of suicide, 
history of bipolar/dementia/psychotic 
disorder, previous treatment with 
NAC or naltrexone, abnormal LFT's, 
current opiate use 
  Sex (% male/female) 
57.1% male intervention, 82.4% 
control 
  Age (mean, SD) 
37.2(8.2) intervention, 36.1 (6.6) 
control 
  
Ethnicity (%white, % African 
American, % other) 
100% Caucasian intervention, 94.1% 
control, 5.9% African American 
control 
  Employment Status NR 
  Frequency of MA use 
Days used in past 2 weeks 8.08 (4.9) 
intervention, 6.29 (4.6) control 
  Years of MA use 
NR. Did report age at first using MA 
23.4 (9.2) intervention, 25.0 (6.7) 
control 
  Route (injection, smoking, nasal, oral) NR 
  
Comorbid drug disorders (% with 
comorbid drug disorders) 92.9% intervention, 58.5% control 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 42.9% intervention, 75% control 
  Name of drug NAC plus naltrexone 
  Dose 
NAC escalating to 2400mg/d, 
naltrexone escalating to 200mg/d 
  Control placebo 
  Adherence NR 
  Adjunct interventions None 
Outcomes 
Methamphetamine use as determined 
by UDS  
Percentage of positive UDS not 
significantly different 46.2% 
intervention 35.3% intervention 
p=0.547 
  Self-reported meth use 
Change in mean days of drug use in 
past 2 weeks not significantly 
different,  -85.2% intervention vs 




  Methamphetamine craving 
No significant decline in Penn 
Craving Scale total score -43.6% vs -
37.7% p=0.106 
  Retention in Treatment 
No significant difference in study 
completion, 64.3% intervention, 
47.1% control, p= 0.337 
  Number of patients who finished study 17 completed all five visits 
  Reason for drop outs NR 
  Clinical Global Impression score 
Decrease in CGI not significantly 
different -1.71 intervention, -1.24 
control, p=0.498 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  





Author Jayaram-Lindström et al 
Year 2008 
  {JayaramLindstrom:2008kx} 
1. Random Sequence Generation 
(Selection Bias) Unclear risk 
1. Support 
Computer generated, but not specified as to what 
method to achieve 1:1 ratio 
2. Allocation concealment (selection 
bias) Low risk 
2. Support Allocation known only to off-site pharmacy 
3. Blinding of participants and 
providers (performance bias) 
Objective Outcomes Low risk 
3. Support 
Blinding done, low risk of unblinding given mild 
effects of study drug 
4. Blinding of participants and 
providers (performance bias) 
Subjective Outcomes Low risk 
4. Support 
Blinding done, low risk of unblinding given mild 
effects of study drug 
5. Blinding of Outcome Assessor 
objective outcomes (detection bias) Low risk 




6. Blinding of outcome assessor 
subjective outcomes (detection bias) Low risk 
6. Support Blinding done 
7. Incomplete outcome data (attrition 
bias) High risk 
7. Support High attrition rate, reasons for drop outs not given 
8. Selective reporting (reporting bias) Low risk 
8. Support All stated and expected outcomes reported 
9. Other bias High risk 
9. Support Baseline imbalance in severity of amphetamine use. 
10. Overall Judgement of Internal 
Validity (good, fair, poor) Fair 
11. External Validity Poor 
11. Support 
The majority of  participants used a mixture of 
dextro-/levo-amphetamine, and only 16% had UDS 
evidence for methamphetamine. Furthermore, almost 
half of participants had a diagnosis of ADHD. 
Unclear if these results would be the same in 
primarily methamphetamine using population 
Study 
description 
and funding Author Jayaram-Lindström et al 
  Year 2008 
    {JayaramLindstrom:2008kx} 
  Type RCT 
  Country Sweden 
  
Author Conflict of Interest 
(pharmaceutical industry yes/no)? Yes 
  
Study funding (pharmaceutical 
company yes/no) No 
Methods Sequence Generation 
Computerized randomization, not 
further described 
  Allocation Concealment 




patients/clinicians/therapists/assessors Stated as double blind 
  Design: single site/multiple single 
  Study duration 12 weeks 
  Number of participants 80 
  
Handling of dropouts (ITT or per 
protocol) 
All missing urine samples analyzed 
as positive. 
  
Instruments used to assess study 
outcomes 
UDS twice weekly, Addiction 
Severity Index (ASI), self report, 




Participants Source Population 
newspaper advertisements and 
social workers 
  Inclusion Criteria 
age 20-65, DSM-IV amphetamine 
dependence, used amphetamine at 
least 12 days in past 12 weeks 
  Exclusion Criteria 
Positive UDS during 2 week lead-
in. DSM-IV diagnosis of other 
substance dependence except 
nicotine, h/o major psychiatric 
disorder, current condition requiring 
medication, use of an opioid in last 
month, current benzo use, UDS 
positive for other substances, 
serious medical disease, pregnancy 
or lactation 
  Sex (% male/female) 
Male 77.5% intervention, 80% 
control 
  Age (mean, SD) 
39.3 (8.1) intervention, 39.6 (9.3) 
control 
  
Ethnicity (%white, % African 
American, % other) NR 
  Employment Status NR 
  Frequency of MA use 
Days of use in the 12 weeks prior: 
30.9 intervention, 27.3 control  
  Years of MA use 10.42 intervention, 9.97 control 
  Route (injection, smoking, nasal, oral) 
IV 65% intervention, 76% control; 
Oral 35% intervention, 25% control 
  
Comorbid drug disorders (% with 
comorbid drug disorders) 
Those with DSM-IV dependence 
excluded from study. Days of 
alcohol use in 12 weeks prior 30.9 
intervention, 27.3 control. 
  
Comorbid disorders (% with comorbid 
psychiatric disorders) 
ADHD 47.5% intervention, 45% 
control. Other disorders excluded 
from study 
  Name of drug naltrexone 
  Dose 50mg 
  Control placebo in matching blister package 
  Adherence 
By urine test of beta-naltrexol 25/40 
in naltrexone group had more than 8 
positive out of 12 weekly tests. No 
difference in pill count between 
groups. 
  Adjunct interventions 
Manual based relapse prevention 





Methamphetamine use as determined 
by UDS  
Naltrexone had significantly higher 
number of negative UDS, 65.2% 
intervention, 47.7% control, p<0.05 
  Self-reported meth use 
Significantly larger change in report 
of days used: 52.2% to 5.5% 
intervention, 38.7% to 16.1% 
control, p<0.05 
  Methamphetamine craving 
Intervention group "had a greater 
reduction in craving scores" p<0.05 
  Retention in Treatment 
72.5% in intervention, 65% in 
control retained to end of study 
  
Number of patients who finished 
study 55 (68.8%)  
  Reason for drop outs 
inability to comply with weekly 
attendance at clinic 
  Clinical Global Impression score NR 
  Psychotic symptoms NR 
  Anxiety symptom severity NR 
  Depression symptom severity NR 
  Cocaine use by UDS NR 
  Opiate use by UDS NR 
  
Number dropped out due to adverse 
events 0 
  
Number who had serious adverse 
events 0 
 
 
